About Centessa Pharmaceuticals
Centessa Pharmaceuticals is a company based in Boston (United States) founded in 2021 was acquired by Lilly in March 2026. Centessa Pharmaceuticals has raised $250 million across 1 funding round from investors including Lilly, T. Rowe Price and General Atlantic. The company has 77 employees as of December 31, 2024. Centessa Pharmaceuticals has completed 1 acquisition, including Apcintex. Centessa Pharmaceuticals offers products and services including Orexin Receptor 2 Agonist Program and LockBody Technology Platform. Centessa Pharmaceuticals operates in a competitive market with competitors including Actelion, Biogen, ADMA Biologics, Kymeratx and BioNTech, among others.
- Headquarter Boston, United States
- Employees 77 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Centessa Pharmaceuticals Plc Adr
-
Annual Revenue
Not available
-
Net Profit
-$235.86 M (USD)-55.51as on Dec 31, 2024
-
EBITDA
-$200.2 M (USD)-16.98as on Dec 31, 2024
-
Total Equity Funding
$250 M (USD)
in 1 rounds
-
Latest Funding Round
$250 M (USD), Series A
Feb 16, 2021
-
Investors
Lilly
& 14 more
-
Employee Count
77
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Lilly
(Mar 31, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Centessa Pharmaceuticals
Centessa Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Centessa Pharmaceuticals
Centessa Pharmaceuticals offers a comprehensive portfolio of products and services, including Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Develops agonists for treating sleep-wake and neurological disorders
Enables innovative medicine development for various disorders
People of Centessa Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Centessa Pharmaceuticals
Centessa Pharmaceuticals has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Series A round of $250 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Centessa Pharmaceuticals
Centessa Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, T. Rowe Price and General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Centessa Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Centessa Pharmaceuticals
Centessa Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Apcintex.
Investment portfolio details for Centessa Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Anti-coagulant targeting APC pathway is developed for haemophilia treatment.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Centessa Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Centessa Pharmaceuticals
Detailed financials for Centessa Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Centessa Pharmaceuticals Comparisons
Peer comparison for Centessa Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Centessa Pharmaceuticals
Centessa Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Biogen, ADMA Biologics, Kymeratx and BioNTech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Centessa Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Centessa Pharmaceuticals
Complete news archive for Centessa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centessa Pharmaceuticals
Centessa Pharmaceuticals was founded in 2021.
Centessa Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Centessa Pharmaceuticals is a funded company, having raised a total of $250M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Centessa Pharmaceuticals is 77.
Centessa Pharmaceuticals was founded in 2021 and is headquartered in Boston, United States. Medicines targeting sleep-wake disorders, neurological conditions, neurodegenerative diseases, and psychiatric issues are developed within the biotechnology sector. Operations encompass discovery through late-stage development of potential first-in-class and best-in-class therapies for rare diseases and immuno-oncology indications. Efforts are directed toward addressing unmet medical needs across these areas.
Centessa Pharmaceuticals's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Centessa Pharmaceuticals offers Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Yes, Centessa Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNTA.
Centessa Pharmaceuticals has made 1 acquisition, including Apcintex.
Centessa Pharmaceuticals has 15 investors. Key investors include Lilly, T. Rowe Price, General Atlantic, Janus Henderson Investors, and Vida Ventures.
The ticker symbol of Centessa Pharmaceuticals is CNTA on NASDAQ.